Alnylam Presents Final Phase I Data on First-Generation Amyloidosis Drug
May 10, 2012
Alnylam Presents Final Phase I Data on First-Generation Amyloidosis Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs
February 14, 2013 / Gene Silencing News - Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - Isis to Receive $1.1M from Alnylam
October 25, 2012 / Gene Silencing News - Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
August 2, 2012 / Gene Silencing News - Alnylam Provides Timelines for Drug Programs, Offers No Formal Guidance on Partnerships
February 16, 2012 / Gene Silencing News